A novel use of AIDS surveillance data to assess the impact of initial treatment regimen on survival

International Journal of STD and AIDS

Volumn 20, Issue 5, 2009, Pages 330-335

  Chen, S Y ^a,b   Moss, W J ^b   Pipkin, S S ^a   McFarland, W ^a,c  

^a SAN FRANCISCO DEPARTMENT OF PUBLIC HEALTH   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^c NONE   (United States)

Author keywords

AIDS; Antiretroviral therapy; Mortality; San Francisco; Surveillance

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; EFAVIRENZ; LOPINAVIR; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; TENOFOVIR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADOLESCENT; ADULT; ARTICLE; CASE CONTROL STUDY; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE SEVERITY; DISEASE SURVEILLANCE; FEMALE; HEALTH INSURANCE; HEALTH SERVICE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOME ASSESSMENT; PRACTICE GUIDELINE; PRIORITY JOURNAL; PUBLIC HEALTH SERVICE; SENESCENCE; SURVIVAL; UNITED STATES;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADOLESCENT; ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CASE-CONTROL STUDIES; FEMALE; HIV-1; HUMANS; MALE; MIDDLE AGED; POPULATION SURVEILLANCE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SAN FRANCISCO; TREATMENT OUTCOME;

EID: 66349112721     PISSN: 09564624     EISSN: None     Source Type: Journal    
DOI: 10.1258/ijsa.2008.008381     Document Type: Article

References (17)

1. The Global Fund to fight AIDS, Tuberculosis and Malaria. Investing in Impact: Mid-year Results Report 2006. Geneva. pp. 1-80.: Available at http://www.theglobalfund.org/en/files/about/replenishment/progress-report- midyear-2006.pdf (last accessed 22 January 2007)
2. Castro KG, Ward JW, Slutsker L, Buehler JW, Jaffe HW, Berkelman RL. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR 1992;41:1-19
3. Schwarcz SK, Hsu LC, Parisi MK, Katz MH. The impact of the 1993 AIDS case definition on the completeness and timeliness of AIDS surveillance. AIDS 1999;13:1109-1114
4. Fauci A. Host factors in HIV disease. Program and Abstracts of the XIII International AIDS Conference; 9-14 July 2000; Durban, South Africa. Session TuOr36
5. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. Atlanta: US DHHS, 2004. Available at http://aidsinfo.nih.gov/ contentfiles/AdultandAdolescentGL.pdf (accessed 25 January 2007)
6. 6 Olsen CH, Gatell J, Ledergerber B, et al. Risk of AIDS and death at given HIV-RNA and CD4 cell counts, in relation to specific antiretroviral drugs in the regimen. AIDS 2005;19:319-330 (Pubitemid 40396564)
7. 7 MacArthur RD, Novak RM, Peng G, et al. A comparison of three highly active antiretroviral treatment strategies consisting of non-nucleoside reverse transcriptase inhibitors, protease inhibitors, or both in the presence of nucleoside reverse transcriptase inhibitors as initial therapy (CPCRA 058 FIRST Study): a long-term randomized trial. Lancet 2006;368:2125-2135 (Pubitemid 44894557)
8. 8 Van Leth F, Phanuphak P, Ruxrungtham K, et al. Comparison of first-line antiretroviral therapy with regimens including Nevirapine, Efavirenz, or both drugs, plus Stavudine and Lamivudine: a randomized open-label trial, the 2NN Study. Lancet 2004;363:1253-1263 (Pubitemid 38496486)
9. The World Health Organization. HIV/AIDS Care and Treatment: Guide for Implementation. 2004 Geneva. pp. 65-68.Available at http://www.wpro.who.int/NR/ rdonlyres/49BC4F23-0DCC-4D28-A50A-4F755BC475EE/0/HIV-AIDS-Care-and-Treatment- Guide-for-Implementation.pdf (accessed 23 May 2007)
10. 10 Viard JP, Mocroft A, Chiesi A, et al. Influence of age on CD4 cell recovery in human immunodeficiency virus-infected patients receiving highly active antiretroviral therapy: evidence from the EuroSIDA study. J Infect Dis 2001;183:1290-1294 (Pubitemid 32281572)
11. 11 Bacchetti P, Osmond D, Chaisson RE, et al. Survival patterns of the first 500 patients with AIDS in San Francisco. J Infect Dis 1988;157:1044-1047 (Pubitemid 18118586)
12. 12 McFarland W, Chen S, Hsu L, Schwarcz S, Katz M. Low socioeconomic status is associated with a higher rate of death in the era of highly active antiretroviral therapy, San Francisco. J Acquir Immune Defic Syndr 2003;33:96-103 (Pubitemid 36547247)
13. Jain S, Schwarcz S, Katz M, Gulati R, McFarland W. Elevated risk of death for African Americans with AIDS, San Francisco, 1996-2002. J Health Care Poor Underserved 2006;17:493-503
14. Nash D, Katyal M, Shah S. Trends in predictors of death due to HIV-related causes among persons living with AIDS in New York City: 1993:2001. J Urban Health 2005;82:584-600
15. Jensen-Fangel S, Pedersen C, Nielsen H, et al. Use of the protease inhibitor Saquinavir hard gel in human immunodeficiency virus-infected patients in the early period of highly active antiretroviral therapy: does it affect long-term treatment outcome? Scand J Infect Dis 2003;35:743-749
16. Bartlett JG. In: Dunning RW, ed. Pocket Guide to Adult HIV/AIDS treatment, Baltimore: Johns Hopkins University, 2005: p. 42
17. 17 Kuritzkes DR, Boyle BA, Gallant JE, Squires KE, Zolopa A. Current management challenges in HIV: antiretroviral resistance. AIDS Read 2003;13:133-142 (Pubitemid 36350429)